30% med både Rebif 22 og 44 mikrogram i forhold til placebo og i løbet af fire år med 22% for Rebif 22 mikrogram og 29% for Rebif 44 mikrogram.
Relapses were reduced by about 30% over two years for both Rebif 22 and 44 micrograms compared with placebo, and by 22% (Rebif 22 micrograms) and 29% (Rebif 44 micrograms) over four years.